Formulation à libération prolongée comprenant un agoniste de GPR119 et un inhibiteur de DPP-IV

• 收藏
• 分享

专利权人:

Arena Pharmaceuticals; Inc.

发明人:

申请号：

EP10010819.0

公开号：

EP2322151A3

申请日:

2006.01.09

申请国别(地区):

EP

年份:

2012

代理人:

摘要：

The present invention concerns combination of an amount of a GPR1 19 agonist with an amount of a dipeptidyl peptidase IV (DPP-IV) inhibitor such that the combination provides an effect in lowering a blood glucose level or in increasing a blood GLP-I level in a subject over that provided by the amount of the GPR1 19 agonist or the amount of the DPP-FV inhibitor alone and the use of such a combination for treating or preventing diabetes and conditions related thereto or conditions ameliorated by increasing a blood GLP-I level.The present invention also relates to the use of a G protein-coupled receptor to screen for GLP-I secretagogues.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/